Evidence map›Paper›PMID 38232612›Full record

SynthesisESMO open2024

Effect of immunotherapy-infusion time of day on survival of patients with advanced cancers: a study-level meta-analysis.

T Landré, A Karaboué, Z S Buchwald, P F Innominato, D C Qian, J B Assié, C Chouaïd, F Lévi, B Duchemann

Registry-linked trialOpen access · goldAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in ESMO open, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07661966 (A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint Blockade), which is not on this map. Cited by 64 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
64citing papers in PubMed, 2 pooled it
16.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07661966 nanot yet recruitingnot on this mapstarted 2026, after this paper: background citation

A Pilot Trial of Bright Light Therapy in Patients Receiving First Line Immune Checkpoint Blockade

TypeinterventionalSponsorWeill Medical College of Cornell UniversityRan2026 to 2027Enrolled12ConditionsMelanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)ArmsBright Light Therapy
3 · Its place in the literature

Who cites it

64 citing papers in PubMed, 2 syntheses or guidelines pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Article
  7. The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026
    Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Cancer Chemoimmunotherapy: Time Will Tell.Cancer immunology research · 2026
    Article
  15. Review
  16. Article
  17. Timing matters: how mechanism-guided sequencing shapes the efficacy of radiotherapy-immunotherapy combinations : A systematic review.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026
    Review
  18. Review
  19. Review
  20. Article

4 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 6 institutions in 3 countries.

T LandréHôpitaux Universitaires Paris Saint-Denis, UCOG, Assistance Publique - Hôpitaux de Paris, Sevran.
A KarabouéMedical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil; UPR 'Chronotherapy, Cancer and Transplantation', Paris-Saclay University Medical School, Villejuif, France.
Z S BuchwaldDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
P F InnominatoOncology Department, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor; Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK.
D C QianDepartment of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, USA.
J B AssiéPneumology Service, CHI Créteil, Créteil; Inserm U955, UPEC, IMRB, Créteil.
C ChouaïdPneumology Service, CHI Créteil, Créteil; Inserm U955, UPEC, IMRB, Créteil.
F LéviUPR 'Chronotherapy, Cancer and Transplantation', Paris-Saclay University Medical School, Villejuif, France; Cancer Research Centre, Division of Biomedical Sciences, Warwick Medical School, University of Warwick, Coventry, UK; Gastro-intestinal and Medical Oncology Service, Paul-Brousse Hospital, Assistance Publique - Hôpitaux de Paris, Villejuif.
B DuchemannThoracic and Medical Oncology Unit, Avicenne Hospital, Assistance Publique - Hôpitaux de Paris, Bobigny, France. Electronic address: boris.duchemann@aphp.fr.
Emory University · USInserm · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRBetsi Cadwaladr University Health Board · GBUniversité Sorbonne Paris Nord · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundImmune checkpoint inhibitors (ICIs) have become the standard of care for numerous malignancies. Emerging evidence suggests that the time of day (ToD) of ICI administration could impact the outcomes of patients with cancer. The consistency of ToD effects on ICI efficacy awaits initial evaluation. MATERIALS AND

methodsThis meta-analysis integrates progression-free survival (PFS) and overall survival (OS) data from studies with a defined 'cut-off' ToD. Hazard ratios (HRs) [95% confidence interval (CI)] of an earlier progression or death according to 'early' or 'late' ToD of ICIs were collected from each report and pooled.

resultsThirteen studies involved 1663 patients (Eastern Cooperative Oncology Group performance status 0-1, 83%; males/females, 67%/33%) with non-small-cell lung cancer (47%), renal cell carcinoma (24%), melanoma (20%), urothelial cancer (5%), or esophageal carcinoma (4%). Most patients received anti-programmed cell death protein 1 or anti-programmed death-ligand 1 (98%), and a small proportion also received anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4) (18%). ToD cut-offs were 13:00 or 14:00 (i.e. ICI median infusion time), for six studies, and 16:00 or 16:30 (i.e. reported threshold for weaker vaccination responses) for seven studies. Pooled analyses revealed that the early ToD groups had longer OS (HR 0.50, 95% CI 0.42-0.58; P < 0.00001) and PFS (HR 0.51, 95% CI 0.42-0.61; P < 0.00001) compared with the late ToD groups.

conclusionsPatients with selected metastatic cancers seemed to largely benefit from early ToD ICI infusions, which is consistent with circadian mechanisms in immune-cell functions and trafficking. Prospective randomized trials are needed to establish recommendations for optimal circadian timing of ICI-based cancer therapies.

Indexed as

Carcinoma, Non-Small-Cell LungKidney NeoplasmsLung NeoplasmsFemaleHumansImmunotherapyMaleProspective Studieschronotherapycircadian rhythmsimmune checkpoint inhibitorsimmunotherapymeta-analysis

Identifiers

PMID38232612
PMCPMC10937202
OpenAlexW4390988653

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.